The characteristics and pivotal roles of triggering receptor expressed on myeloid cells-1 in autoimmune diseases

• Published in: Autoimmunity reviews Vol. 18; no. 1; pp. 25 - 35
• Main Authors: Gao, Sheng, Yi, Yongdong, Xia, Guojun, Yu, Chengyang, Ye, Chenmin, Tu, Fuyang, Shen, Leibin, Wang, Wenqian, Hua, Chunyan
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.01.2019
• Subjects: Autoimmune disease; Inflammation; Therapy; TREM-1; Therapy; SSc; T1D; PRRs; DAP12; Autoimmune disease; IBD; HIF-1α; HMGB1; Cbl; Elk1; SLE; MPO; UC; NFAT; ECs; PI3K; DCs; PGRPs; PAMPs; CIA; PGLYRP1; CKD; BAFF; CD; NOD; HSP70; JIA; SYK; PLC-γ; Inflammation; RAGE; IIM; RA; TREM-1; ZAP70; SOS; GRB2; NLRs; HLA; TLRs
• ISSN: 1568-9972; 1568-9972; 1873-0183
• DOI: 10.1016/j.autrev.2018.07.008

Triggering receptor expressed on myeloid cells-1 (TREM-1) engagement can directly trigger inflammation or amplify an inflammatory response by synergizing with TLRs or NLRs. Autoimmune diseases are a family of chronic systemic inflammatory disorders. The pivotal role of TREM-1 in inflammation makes it important to explore its immunological effects in autoimmune diseases. In this review, we summarize the structural and functional characteristics of TREM-1. Particularly, we discuss recent findings on TREM-1 pathway regulation in various autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), type 1 diabetes (T1D), and psoriasis. This receptor may potentially be manipulated to alter the inflammatory response to chronic inflammation and possible therapies are explored in this review. •TREM-1 engagement directly induces or amplifies inflammatory responses.•TREM-1 expression was dysregulated in inflammatory autoimmune diseases.•TREM-1 may serve as a promising therapeutic target for autoimmune disease.